Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +48.08%
#3 Akedo Akedo +40.50%
#4 Velvet Velvet +35.26%
#5 Black Phoenix Black Phoenix +34.23%
#6 Cross Cross +19.18%
#7 DoubleZero DoubleZero +18.36%
#8 Tutorial Tutorial +15.48%
#9 Cap Cap +14.84%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.23%
Coin of the day
Islamic Coin Islamic Coin
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Novan, Inc. Novan, Inc.

Novan, Inc.

NOVN
Rang in aandelen #39525
Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in... Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in nitric oxide-derived therapies for dermatological and anti-infective conditions. The company boasts a robust clinical-stage pipeline featuring several topical drug candidates. For skin-related ailments, these include SB204, a monotherapy aimed at acne vulgaris; SB206, an antiviral gel targeting viral skin infections; SB208, a broad-spectrum antifungal gel designed to combat various fungal skin and nail infections like athlete's foot; and SB414, a cream-based gel formulated for inflammatory skin diseases. Additionally, Novan is advancing SB207 to treat external genital warts, WH602 (an intravaginal gel) and WH504 (a non-gel formulation) both addressing high-risk human papillomavirus (HPV), and SB019, a candidate for SARS-CoV-2. The firm has cultivated strategic partnerships, holding a licensing agreement with Sato Pharmaceutical Co., Ltd., and engaging in a strategic alliance with Orion Corporation. Founded in 2006, Novan, Inc. maintains its headquarters in Durham, North Carolina.
Aandeelprijs
$0.056
Laatst gesynchroniseerd: 2023-08-21
Marktkapitalisatie
$451.38K
Verandering (1 dag)
8.74%
Verandering (1 jaar)
0.00%
Land
US
Handel Novan, Inc. (NOVN)

Categorie

Healthcare
Winst voor Novan, Inc. (NOVN)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Novan, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Novan, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE